Global Recombinant Human Insulin Market Research Report 2024

Publication ID:

PB502245911

Publication Date:

March 6, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Insulin is a well-characterized peptide that can be produced byrecombinant听DNA technology for听human听therapeutic use.
The global Recombinant Human Insulin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Recombinant Human Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Recombinant Human Insulin is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Recombinant Human Insulin include Akron Biotech, Wockhardt, Dance Biopharm, Novo Nordisk, Gan & Lee, United Laboratories and Dongbro Pharmaceuticri, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Recombinant Human Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Human Insulin.
Report Scope
The Recombinant Human Insulin market size, estimations, and forecasts are provided in terms of sales volume (g) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant Human Insulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Human Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Akron Biotech
Wockhardt
Dance Biopharm
Novo Nordisk
Gan & Lee
United Laboratories
Dongbro Pharmaceuticri
Segment by Type
by Recombinant DNA Technology Using Fermentation in Bacteria Way
by Recombinant DNA Technology Using Fermentation in Yeast Way
Segment by Application
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Human Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Human Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Recombinant Human Insulin Market Overview
1.1 Product Overview and Scope of Recombinant Human Insulin
1.2 Recombinant Human Insulin Segment by Recombinant DNA Technology Using Fermentation in Bacteria Way
1.2.1 Global Recombinant Human Insulin Market Value Comparison by Recombinant DNA Technology Using Fermentation in Bacteria Way (2024-2030)
1.2.2 by Recombinant DNA Technology Using Fermentation in Bacteria Way
1.2.3 by Recombinant DNA Technology Using Fermentation in Yeast Way
1.3 Recombinant Human Insulin Segment by Application
1.3.1 Global Recombinant Human Insulin Market Value by Application: (2024-2030)
1.3.2 Type 1 Diabetes Mellitus
1.3.3 Type 2 Diabetes Mellitus
1.4 Global Recombinant Human Insulin Market Size Estimates and Forecasts
1.4.1 Global Recombinant Human Insulin Revenue 2019-2030
1.4.2 Global Recombinant Human Insulin Sales 2019-2030
1.4.3 Global Recombinant Human Insulin Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Recombinant Human Insulin Market Competition by Manufacturers
2.1 Global Recombinant Human Insulin Sales Market Share by Manufacturers (2019-2024)
2.2 Global Recombinant Human Insulin Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Recombinant Human Insulin Average Price by Manufacturers (2019-2024)
2.4 Global Recombinant Human Insulin Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Human Insulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Human Insulin, Product Type & Application
2.7 Recombinant Human Insulin Market Competitive Situation and Trends
2.7.1 Recombinant Human Insulin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Recombinant Human Insulin Players Market Share by Revenue
2.7.3 Global Recombinant Human Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Human Insulin Retrospective Market Scenario by Region
3.1 Global Recombinant Human Insulin Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Recombinant Human Insulin Global Recombinant Human Insulin Sales by Region: 2019-2030
3.2.1 Global Recombinant Human Insulin Sales by Region: 2019-2024
3.2.2 Global Recombinant Human Insulin Sales by Region: 2025-2030
3.3 Global Recombinant Human Insulin Global Recombinant Human Insulin Revenue by Region: 2019-2030
3.3.1 Global Recombinant Human Insulin Revenue by Region: 2019-2024
3.3.2 Global Recombinant Human Insulin Revenue by Region: 2025-2030
3.4 North America Recombinant Human Insulin Market Facts & Figures by Country
3.4.1 North America Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Recombinant Human Insulin Sales by Country (2019-2030)
3.4.3 North America Recombinant Human Insulin Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Human Insulin Market Facts & Figures by Country
3.5.1 Europe Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Recombinant Human Insulin Sales by Country (2019-2030)
3.5.3 Europe Recombinant Human Insulin Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Human Insulin Market Facts & Figures by Country
3.6.1 Asia Pacific Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Recombinant Human Insulin Sales by Country (2019-2030)
3.6.3 Asia Pacific Recombinant Human Insulin Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Human Insulin Market Facts & Figures by Country
3.7.1 Latin America Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Recombinant Human Insulin Sales by Country (2019-2030)
3.7.3 Latin America Recombinant Human Insulin Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Human Insulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Human Insulin Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Recombinant Human Insulin Sales by Country (2019-2030)
3.8.3 Middle East and Africa Recombinant Human Insulin Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Human Insulin Sales by Type (2019-2030)
4.1.1 Global Recombinant Human Insulin Sales by Type (2019-2024)
4.1.2 Global Recombinant Human Insulin Sales by Type (2025-2030)
4.1.3 Global Recombinant Human Insulin Sales Market Share by Type (2019-2030)
4.2 Global Recombinant Human Insulin Revenue by Type (2019-2030)
4.2.1 Global Recombinant Human Insulin Revenue by Type (2019-2024)
4.2.2 Global Recombinant Human Insulin Revenue by Type (2025-2030)
4.2.3 Global Recombinant Human Insulin Revenue Market Share by Type (2019-2030)
4.3 Global Recombinant Human Insulin Price by Type (2019-2030)
5 Segment by Application
5.1 Global Recombinant Human Insulin Sales by Application (2019-2030)
5.1.1 Global Recombinant Human Insulin Sales by Application (2019-2024)
5.1.2 Global Recombinant Human Insulin Sales by Application (2025-2030)
5.1.3 Global Recombinant Human Insulin Sales Market Share by Application (2019-2030)
5.2 Global Recombinant Human Insulin Revenue by Application (2019-2030)
5.2.1 Global Recombinant Human Insulin Revenue by Application (2019-2024)
5.2.2 Global Recombinant Human Insulin Revenue by Application (2025-2030)
5.2.3 Global Recombinant Human Insulin Revenue Market Share by Application (2019-2030)
5.3 Global Recombinant Human Insulin Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Akron Biotech
6.1.1 Akron Biotech Corporation Information
6.1.2 Akron Biotech Description and Business Overview
6.1.3 Akron Biotech Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Akron Biotech Recombinant Human Insulin Product Portfolio
6.1.5 Akron Biotech Recent Developments/Updates
6.2 Wockhardt
6.2.1 Wockhardt Corporation Information
6.2.2 Wockhardt Description and Business Overview
6.2.3 Wockhardt Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Wockhardt Recombinant Human Insulin Product Portfolio
6.2.5 Wockhardt Recent Developments/Updates
6.3 Dance Biopharm
6.3.1 Dance Biopharm Corporation Information
6.3.2 Dance Biopharm Description and Business Overview
6.3.3 Dance Biopharm Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Dance Biopharm Recombinant Human Insulin Product Portfolio
6.3.5 Dance Biopharm Recent Developments/Updates
6.4 Novo Nordisk
6.4.1 Novo Nordisk Corporation Information
6.4.2 Novo Nordisk Description and Business Overview
6.4.3 Novo Nordisk Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novo Nordisk Recombinant Human Insulin Product Portfolio
6.4.5 Novo Nordisk Recent Developments/Updates
6.5 Gan & Lee
6.5.1 Gan & Lee Corporation Information
6.5.2 Gan & Lee Description and Business Overview
6.5.3 Gan & Lee Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Gan & Lee Recombinant Human Insulin Product Portfolio
6.5.5 Gan & Lee Recent Developments/Updates
6.6 United Laboratories
6.6.1 United Laboratories Corporation Information
6.6.2 United Laboratories Description and Business Overview
6.6.3 United Laboratories Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.6.4 United Laboratories Recombinant Human Insulin Product Portfolio
6.6.5 United Laboratories Recent Developments/Updates
6.7 Dongbro Pharmaceuticri
6.6.1 Dongbro Pharmaceuticri Corporation Information
6.6.2 Dongbro Pharmaceuticri Description and Business Overview
6.6.3 Dongbro Pharmaceuticri Recombinant Human Insulin Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Dongbro Pharmaceuticri Recombinant Human Insulin Product Portfolio
6.7.5 Dongbro Pharmaceuticri Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Human Insulin Industry Chain Analysis
7.2 Recombinant Human Insulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Human Insulin Production Mode & Process
7.4 Recombinant Human Insulin Sales and Marketing
7.4.1 Recombinant Human Insulin Sales Channels
7.4.2 Recombinant Human Insulin Distributors
7.5 Recombinant Human Insulin Customers
8 Recombinant Human Insulin Market Dynamics
8.1 Recombinant Human Insulin Industry Trends
8.2 Recombinant Human Insulin Market Drivers
8.3 Recombinant Human Insulin Market Challenges
8.4 Recombinant Human Insulin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Akron Biotech
Wockhardt
Dance Biopharm
Novo Nordisk
Gan & Lee
United Laboratories
Dongbro Pharmaceuticri

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂